A Model Experiment
Harnessing the potential of microphysiological systems to advance drug discovery
Audrey Dubourg | | Opinion
With just one in 10 preclinical candidates in phase I trials likely to gain market approval, the pharmaceutical industry must find ways to develop effective therapeutics faster and more cost-effectively. Pipelines include a mix of drug discovery, redevelopment, repurposing, combination therapeutics, and new modalities, such as gene therapies or regenerative medicines. When it comes to success, however, the translatability of preclinical data into clinical efficacy is only as good as the predictivity of the test models…
Drug discovery traditionally involves two-dimensional monolayer cell culture experiments followed by testing in animals to ensure results translate in vivo. Unfortunately, these models suffer from well-documented inefficiencies and inaccuracies, including oversimplification, insufficient representation of the underlying pathophysiology, and interspecies differences – all of which can lead to poor translatability into the clinic.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine